| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -92,673 | -81,490 |
| Stock-based compensation | 27,803 | 18,237 |
| Change in fair value of cvr liability | 42,199 | 1,800 |
| Gain on sale of in-process research and development asset | 10,000 | 10,000 |
| Net accretion of discount on marketable securities | 6,005 | 4,655 |
| Interest proceeds from maturities of zero coupon u.s. treasury bills | 2,069 | 1,760 |
| Accounts payable | 6,791 | 3,046 |
| Accrued and other liabilities | -3,888 | -8,299 |
| Related party accounts payable | 3,367 | -572 |
| Prepaid expenses and other assets | 9,939 | 3,784 |
| Net cash used in operating activities | -124,674 | -87,557 |
| Proceeds from maturities and sales of marketable securities | 277,440 | 178,249 |
| Purchases of marketable securities | 180,505 | 106,312 |
| Proceeds from sale of in-process research and development asset | 7,000 | 7,000 |
| Net cash provided by (used in) investing activities | 103,935 | 78,937 |
| Proceeds from issuance of series b non-voting convertible preferred stock in connection with private placement, net of placement and other offering costs | 0 | 0 |
| Cash settlement of employee stock option award | - | 117 |
| Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs | 0 | - |
| Payment of deferred offering costs in connection with shelf registration | 93 | 93 |
| Payments related to cvr | 5,251 | 0 |
| Proceeds from employee stock option exercises and employee stock plan purchases | 1,557 | 1,066 |
| Net cash (used in) provided by financing activities | -3,787 | 856 |
| Effect of exchange rate on cash and cash equivalents | 0 | 0 |
| Net decrease in cash and cash equivalents | -24,526 | -7,764 |
| Cash and cash equivalents at beginning of period | 89,423 | - |
| Cash and cash equivalents at end of period | 64,897 | - |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)